Company Filing History:
Years Active: 2007-2012
Title: Innovator Tania Shane: Pioneering Antibody Research in Newton, MA
Introduction
Tania Shane is a distinguished inventor based in Newton, MA, who has made significant contributions to the field of biotechnology. With three patents to her name, she has demonstrated her expertise in developing antibodies that target human interleukin-13 (IL-13), a cytokine involved in various immune responses and disorders. Her innovative work has the potential to greatly impact the treatment of multiple IL-13-associated conditions.
Latest Patents
Tania Shane's latest patents focus on the development and application of antibodies against human interleukin-13.
1. **Antibodies against human interleukin-13 and uses therefor**: This patent application describes humanized antibodies and antigen-binding fragments that specifically bind to IL-13. These antibodies are designed for diagnosing, preventing, and treating disorders associated with IL-13, such as respiratory issues like asthma, atopic conditions, inflammatory skin disorders like atopic dermatitis, gastrointestinal issues including inflammatory bowel diseases (IBD), as well as fibrotic and cancerous disorders.
2. **Antibodies against human interleukin-13 and pharmaceutical compositions thereof**: Similar to her first patent, this application highlights the potential uses of humanized antibodies that target IL-13. The focus remains on their utility in managing various IL-13-mediated health issues, thereby providing new avenues for clinical intervention.
Career Highlights
Tania Shane has been an integral part of Wyeth, a prominent biopharmaceutical company, where she has been able to leverage her skills and knowledge in biochemistry and immunology. Her research and development work has been crucial in advancing the understanding of IL-13 and identifying therapeutic candidates that could lead to improved treatments for patients suffering from related disorders.
Collaborations
Throughout her career, Tania Shane has collaborated with notable colleagues such as Kevin Delos Parris and Marion T. Kasaian. These partnerships have helped propel innovative ideas and research in the field, further enhancing the potential applications of her inventions in therapeutic settings.
Conclusion
Tania Shane's work exemplifies the spirit of innovation in biotechnology. Through her patents and research endeavors, she has not only contributed to the scientific community but also provided hope for patients suffering from a range of IL-13-associated disorders. Her future endeavors will undoubtedly continue to inspire advancements in immunology and pharmaceutical development, solidifying her place as a key inventor in the field.